De novo radiologic placement of button gastrostomy: a feasibility study in children with cancer.

BACKGROUND: Primary placement of percutaneous radiologic button gastrostomy has been successfully performed in adults but research is lacking as to its success in children during cancer treatment. OBJECTIVE: To assess the safety and effectiveness of such treatment at a single center. MATERIALS AND METHODS: We conducted a 3-year retrospective feasibility study reporting on placement procedure, feeding plan, acute complications and effectiveness of this technique based on the evolution of the weight and weight-to-height during a period of 3 months. RESULTS: Eleven gastrostomies were performed in 11 children and young adults (3-20 years old) during oncological treatment. No major complications occurred. Two patients experienced minor side effects -- local leakage and granulation tissue formation -- both easily treated. In all cases, enteral feeding started within 24 h following the button placement. The patients were able to go home within 72 h. After 1 month, 64% (7/11) had gained weight, 18% (2/11) had maintained weight and 9% (1/11) had lost weight. After 3 months, 73% (8/11) had gained weight and 9% (1/11) had lost weight. CONCLUSION: The procedure and devices were well tolerated and mostly effective in our cohort.

Late emergence of contrast-enhancing fat necrosis mimicking tumor seeding after renal cryoablation.

Defining radiographic treatment success after percutaneous renal ablation is challenging due to variable ablation zone imaging findings over time. The present report describes two cases of progressively more evident enhancing soft-tissue nodules in the perinephric fat more than 2 years after cryoablation. Despite features concerning for tumor recurrence on computed tomography and magnetic resonance imaging, biopsies revealed fat necrosis in both cases. Renal ablation zone soft-tissue nodules can appear long after ablation, enhance with contrast medium, mimic applicator tract or ablation zone tumor seeding, and may require biopsy for confirmation of benignity.

Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma.

UNLABELLED: Epithelioid hemangioendothelioma is a rare connective tissue tumor of vascular origin. It is most commonly found in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic tumor to an aggressive rapidly growing neoplasm. Most tumors are diagnosed in an advanced unresectable phase and when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal study. Their activity in EHE has been reported but long term outcome of these patients remain unreported. We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib therapy resulted in clinical improvement of symptoms and durable stabilization of liver tumors and lung lesions. CONCLUSION: Pazopanib is a promising therapeutic option in patients with HEH.